Clinical trial NCT06011200: A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old Population
Official title: A Randomized, Blinded, Comparable Vaccine-controlled Phase IIIb Clinical Trial to Evaluate the Safety and Immunogenicity of Meningococcal Polysaccharide Conjugate Vaccine, Group ACYW135 (CRM197 Vector), in a 4 to 6 Year-old Population
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Epidemic Meningitis
Keywords: ACYW135
CRM197
Immunogenicity
Safety
4~6 yearsof age
Lead sponsor: CanSino Biologics Inc.
Sponsor class: INDUSTRY
First posted: 2023-08-25
Enrollment: 1000
Sex: ALL
Minimum age (years): 4
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The scientific name of meningococcus is Neisseria meningitidis (Nm), the causative agent of epidemic meningococcal meningitis (rheumatoid encephalitis), which colonizes the mucous membranes of the human nasopharynx or causes local infection and can cross the mucosal barrier to cause invasive bacteremia or epidemic meningococcal meningitis, meningococcus can often cause serious disease epidemics worldwide, the main clinical features of its infection are fever, rash and meningitis, the most common clinical manifestation is acute bacterial meningitis.

Detailed description: The preventive measures for influenza are based on strengthening personal protection, vaccination, strengthening surveillance, early detection of patients, and active isolation and treatment. The immune response to meningococcal polysaccharide vaccine is weak in infants under 2 years of age, and only a transient immune response is produced. Numerous experiments have shown that the immunogenicity of polysaccharides is enhanced by binding to protein carriers, and a significant booster effect is produced. Meningococcal polysaccharide conjugate vaccine induces a good immune response in infants and children under 2 years of age and produces immune memory, which enhances the immune effect of the vaccine and can eliminate the carrier state of infected patients.

Eligibility criteria: Inclusion Criteria:

* Children aged 4\~6 years old
* Complete at least two doses of basic immunization with polysaccharide influenza vaccine according to the immunization program
* The legal guardian or delegate has given informed consent, voluntarily signed the informed consent form, and is able to comply with the requirements of the clinical study protocol

Exclusion Criteria:

* Fever before inoculation, axillary temperature \>37.0℃
* Previous history of immunization with meningococcal polysaccharide conjugate vaccine
* Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.
* History of epilepsy, convulsions or seizures or a history of psychiatric illness or family history
* Volunteers with current meningitis or a history of meningitis
* Volunteers treated with immunosuppressive therapy, cytotoxic therapy, glucocorticoids (excluding topical treatment, surface treatment for acute uncomplicated dermatitis, spray treatment for allergic rhinitis) within the past 6 months (\<6 months)
* Received blood/plasma products or immunoglobulins within 60 days (\<60 days) prior to study vaccination or planned to receive blood/plasma products or immunoglobulins throughout the study period
* Suffering from serious chronic diseases or conditions that are in a progressive stage and cannot be controlled smoothly, such as thyroid disease
* Volunteers with known or suspected diseases that are judged by the investigator to affect vaccination such as severe respiratory disease, acute infection or active chronic disease, severe cardiovascular disease, severe liver or kidney disease, malignancy, severe infectious or allergic skin disease
* History of serious adverse reactions associated with the vaccine and/or history of severe allergic reactions (e.g., systemic allergic reactions) to any component of the investigational vaccine
* Immunocompromised individuals with known or suspected immunodeficiency as determined by medical history and/or physical examination (e.g., malignancy, HIV, etc.)
* Bleeding constitution or condition associated with prolonged bleeding, investigators consider intramuscular injection to be contraindicated
* Live attenuated vaccine given within 14 days, other vaccines given within 7 days
* Participation in other studies involving interventions within 28 days (\<28 days) prior to study entry and/or during study participation
* Other conditions judged by the investigator to be inappropriate for participation in this clinical trial

Primary outcomes:
measure: Geometric mean titers (GMT) of meningococcal antibodies to groups A, C, Y and W135 in all subjects 30 days after immunization
timeFrame: 30 days after immunization
measure: Positive conversion rates of meningococcal antibodies to groups A, C, Y and W135 in all subjects 30 days after immunization
timeFrame: 30 days after immunization
measure: Incidence of adverse reactions within 30 minutes after immunization in all subjects
timeFrame: Within 30 minutes after immunization
measure: Incidence of adverse reactions/events within 7 days of immunization for all subjects
timeFrame: Within 7 days after immunization
measure: Incidence of adverse reactions/events within 30 days of exemption for all subjects
timeFrame: Within 30 days of exemption
Secondary outcomes:
measure: Meningococcal positivity for groups A, C, Y, and W135 for all subjects 30 days after immunization
timeFrame: 30 days after immunization
measure: Geometric mean growth multiplier (GMI) for all subjects 30 days after immunization
timeFrame: 30 days after immunization
measure: Antibody titers ≥1:128 ratio for all subjects 30 days after immunization
timeFrame: 30 days after immunization
measure: Meningococcal antibody positivity for groups A, C, Y and W135 at 90 and 180 days of exemption in 500 subjects
timeFrame: 90 and 180 days of exemption
measure: GMT for groups A, C, Y and W135 at 90 and 180 days of exemption in 500 subjects
timeFrame: 90 and 180 days of exemption
measure: GMI for groups A, C, Y and W135 at 90 and 180 days of exemption in 500 subjects
timeFrame: 90 and 180 days of exemption
measure: Antibody titers ≥1:128 ratio for groups A, C, Y and W135 at 90 and 180 days of exemption in 500 subjects
timeFrame: 90 and 180 days of exemption
measure: Incidence of serious adverse events (SAEs) within 180 days of exemption in all subjects
timeFrame: Within 180 days of exemption
measure: All subjects were stratified into susceptible (<1:8) and non-susceptible (≥1:8) populations according to the 1:8 pre-immune antibody titer threshold
timeFrame: 30 days after immunization
Other outcomes:
Locations:
city: Shanyang
country: China
facility: Shanyang County Center for Disease Prevention and Control
state: Shaanxi
Study officials:
References: